127.09
price down icon0.87%   -0.955
 
loading
Novartis Ag Adr stock is traded at $127.09, with a volume of 43,522. It is down -0.87% in the last 24 hours and up +8.64% over the past month. Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
See More
Previous Close:
$128.05
Open:
$127.29
24h Volume:
43,522
Relative Volume:
0.03
Market Cap:
$268.30B
Revenue:
$53.40B
Net Income/Loss:
$13.68B
P/E Ratio:
18.36
EPS:
6.9231
Net Cash Flow:
$16.89B
1W Performance:
-1.01%
1M Performance:
+8.64%
6M Performance:
+9.93%
1Y Performance:
+8.51%
1-Day Range:
Value
$126.90
$127.29
1-Week Range:
Value
$126.90
$130.46
52-Week Range:
Value
$96.06
$130.46

Novartis Ag Adr Stock (NVS) Company Profile

Name
Name
Novartis Ag Adr
Name
Phone
-
Name
Address
-
Name
Employee
75,883
Name
Twitter
@novartis
Name
Next Earnings Date
2025-07-17
Name
Latest SEC Filings
Name
NVS's Discussions on Twitter

Compare NVS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
127.01 249.16B 53.40B 13.68B 16.89B 6.9231
Drug Manufacturers - General icon
LLY
Lilly Eli Co
748.58 662.16B 53.26B 13.80B -50.20M 15.30
Drug Manufacturers - General icon
JNJ
Johnson Johnson
175.42 429.00B 90.62B 22.66B 18.18B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
209.06 370.61B 58.33B 3.73B 18.24B 2.10
Drug Manufacturers - General icon
MRK
Merck Co Inc
84.02 210.04B 63.43B 16.42B 14.72B 6.49

Novartis Ag Adr Stock (NVS) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-08-25 Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-13-25 Downgrade UBS Buy → Neutral
Feb-12-25 Initiated Morgan Stanley Underweight
Feb-04-25 Upgrade Deutsche Bank Hold → Buy
Dec-04-24 Downgrade HSBC Securities Hold → Reduce
Sep-11-24 Downgrade BofA Securities Buy → Neutral
Sep-05-24 Downgrade Goldman Buy → Neutral
Sep-03-24 Downgrade Jefferies Buy → Hold
Jul-19-24 Downgrade Deutsche Bank Buy → Hold
May-30-24 Initiated Goldman Buy
Feb-23-24 Initiated BMO Capital Markets Market Perform
Jan-23-24 Initiated Morgan Stanley Equal-Weight
Jan-16-24 Resumed UBS Buy
Dec-18-23 Downgrade HSBC Securities Buy → Hold
Sep-25-23 Upgrade Morgan Stanley Underweight → Equal-Weight
Jul-14-23 Initiated HSBC Securities Buy
Apr-26-23 Upgrade Deutsche Bank Hold → Buy
Mar-27-23 Upgrade Deutsche Bank Sell → Hold
Jan-26-23 Downgrade Citigroup Buy → Neutral
Dec-05-22 Upgrade Stifel Hold → Buy
Sep-15-22 Downgrade Credit Suisse Neutral → Underperform
Sep-14-22 Downgrade Berenberg Buy → Hold
May-09-22 Downgrade Wolfe Research Outperform → Peer Perform
Jan-10-22 Resumed Citigroup Buy
Dec-14-21 Downgrade Redburn Buy → Neutral
Dec-06-21 Downgrade Exane BNP Paribas Outperform → Neutral
Dec-03-21 Downgrade Bryan Garnier Buy → Neutral
Sep-20-21 Downgrade Deutsche Bank Hold → Sell
Mar-22-21 Initiated Bernstein Mkt Perform
Mar-10-21 Downgrade Argus Buy → Hold
Feb-01-21 Downgrade Cowen Outperform → Market Perform
Jan-15-21 Initiated Deutsche Bank Buy
Sep-29-20 Initiated Berenberg Buy
Sep-10-20 Upgrade UBS Neutral → Buy
Sep-01-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-15-20 Upgrade Citigroup Neutral → Buy
Mar-10-20 Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-20 Downgrade Guggenheim Buy → Neutral
Apr-25-19 Upgrade Guggenheim Neutral → Buy
Apr-25-19 Upgrade Liberum Hold → Buy
Apr-10-19 Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19 Downgrade JP Morgan Neutral → Underweight
Dec-11-18 Resumed Jefferies Buy
Oct-09-18 Initiated Guggenheim Neutral
Sep-10-18 Upgrade BofA/Merrill Underperform → Buy
May-29-18 Downgrade HSBC Securities Buy → Hold
May-25-18 Upgrade Credit Suisse Underperform → Neutral
Jan-25-18 Reiterated Leerink Partners Outperform
Dec-06-17 Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17 Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17 Downgrade Credit Suisse Neutral → Underperform
Mar-09-17 Initiated Liberum Buy
View All

Novartis Ag Adr Stock (NVS) Latest News

pulisher
04:39 AM

Global Industrial Biomanufacturing Market Report 2026-2036: Sustainability, Synthetic Biology, and Circular Economy Drive Growth - GlobeNewswire Inc.

04:39 AM
pulisher
Sep 09, 2025

Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver - sharewise.com

Sep 09, 2025
pulisher
Sep 09, 2025

Novartis strikes $1.4bn deal for Tourmaline Bio - Proactive financial news

Sep 09, 2025
pulisher
Sep 03, 2025

Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.

Sep 03, 2025
pulisher
Sep 03, 2025

Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases - Ariva

Sep 03, 2025
pulisher
Aug 19, 2025

Drug Delivery Devices Market To Grow At 7.90% CAGR Through 2030, Driven By FDA Approvals And Pipeline Advances By Pfizer, J&J, Novartis, Medtronic, And Becton Dickinson Through 2030 Delveinsight - Menafn

Aug 19, 2025
pulisher
Aug 18, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Aug 18, 2025
pulisher
Aug 17, 2025

Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm - sharewise.com

Aug 17, 2025
pulisher
Aug 11, 2025

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease - Novartis

Aug 11, 2025
pulisher
Aug 10, 2025

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease - Ariva

Aug 10, 2025
pulisher
Aug 07, 2025

What’s Next for Pharma Stocks After Trump’s Drug Price Ultimatum? - Morningstar

Aug 07, 2025
pulisher
Jul 31, 2025

Sustainable dividends from European stocks poised to benefit from the tariff wars - The Globe and Mail

Jul 31, 2025
pulisher
Jul 29, 2025

INCY's Q2 Earnings & Revenues Beat Estimates On Higher Product Sales - Barchart.com

Jul 29, 2025
pulisher
Jul 25, 2025

NVS’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Jul 25, 2025
pulisher
Jul 18, 2025

Novartis Holds a Strong Branded Drug Portfolio, Supporting Steady Long-Term Growth - Morningstar

Jul 18, 2025
pulisher
Jul 17, 2025

Novartis Beats On Q2 Earnings And Sales, CFO Retires, Stock Down - Barchart.com

Jul 17, 2025
pulisher
Jul 17, 2025

Novartis ADR earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria

Jul 17, 2025
pulisher
Jul 15, 2025

Will Key Drugs Maintain Momentum For Novartis In Q2 Earnings? - Barchart.com

Jul 15, 2025
pulisher
Jul 15, 2025

Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings? - Yahoo Finance

Jul 15, 2025
pulisher
Jul 10, 2025

Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS) - Barchart.com

Jul 10, 2025
pulisher
Jul 03, 2025

Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study - TradingView

Jul 03, 2025
pulisher
Jul 01, 2025

Incyte Gains 9.2% In Three Months: Buy, Hold Or Sell The Stock? - Barchart.com

Jul 01, 2025
pulisher
Jun 25, 2025

Novartis completes acquisition of Regulus Therapeutics - Novartis

Jun 25, 2025
pulisher
Jun 16, 2025

5 Large Drug Stocks That Are Poised To Ride On Sector Recovery - Barchart.com

Jun 16, 2025
pulisher
Jun 11, 2025

NVO Stock Gains After Parvus Asset Management Builds Stake - Barchart.com

Jun 11, 2025

Novartis Ag Adr Stock (NVS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general MRK
$83.94
price down icon 0.05%
drug_manufacturers_general NVO
$54.13
price down icon 0.11%
$210.16
price up icon 0.13%
$279.25
price down icon 0.36%
$115.19
price down icon 0.40%
Cap:     |  Volume (24h):